EMA Authorised: GoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.) (Budesonide;formoterol fumarate dihydrate) — Teva Pharma B.V.

View source ↗

Summary

The European Medicines Agency authorised GoResp Digihaler, a budesonide/formoterol inhalation therapy by Teva Pharma B.V. (previously Budesonide/Formoterol Teva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GoResp Digihaler (budesonide/formoterol fumarate dihydrate)

Snippet

Status: Authorised. Therapeutic area: Asthma;Pulmonary Disease, Chronic Obstructive. MAH: Teva Pharma B.V.. Decision date: 10/02/2025